SP 100030
Modify Date: 2024-01-19 20:20:25
SP 100030 structure
|
Common Name | SP 100030 | ||
|---|---|---|---|---|
| CAS Number | 154563-54-9 | Molecular Weight | 437.65 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C14H5ClF9N3O | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of SP 100030SP-100030 is a potent NF-κB and activator protein-1 (AP-1) double inhibitor (IC50s=50 and 50 nM, respectively). SP-100030 inhibits IL-2, IL-8, and TNF-alpha production in Jurkat and other T cell lines. SP-100030 decreases murine collagen-induced arthritis (CIA)[1][2]. |
| Name | SP-100030 |
|---|
| Description | SP-100030 is a potent NF-κB and activator protein-1 (AP-1) double inhibitor (IC50s=50 and 50 nM, respectively). SP-100030 inhibits IL-2, IL-8, and TNF-alpha production in Jurkat and other T cell lines. SP-100030 decreases murine collagen-induced arthritis (CIA)[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | SP-100030 blocks the production of IL-2 and IL-8 in Jurkat T-cells at the same concentrations as seen in the luciferase assay (IC50≈30 nM)[1]. ELISA and RT-PCR confirmed that IL-2, IL-8, and TNF-alpha production by activated Jurkat and other T cell lines were inhibited by SP100030[2]. |
| In Vivo | SP100030 (10 mg/kg/day; i.p.; day 21 to day 34) significantly decreased arthritis severity[2]. Animal Model: Six- to 8-wk-old male DBA/1J mice (immunized with type II collagen)[2] Dosage: 10 mg/kg Administration: I.p.; daily, starting at day 21 to the end of the study on day 34 Result: Significantly decreased arthritis scores compared with controls; Histologic evaluation of the paws from mice treated from day 20 to 34 showed a trend toward decreased inflammation. |
| References |
| Molecular Formula | C14H5ClF9N3O |
|---|---|
| Molecular Weight | 437.65 |